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E-cigarettes are indeed less harmful than smoking 
 
Your Editorial1 criticising Public Health England’s review of electronic cigarettes focuses on three 
supposed short-comings of the paper by Nutt et al2: (1) lack of evidence, (2) reliance on the opinions 
of participants, and (3) potential bias arising from the selection of participants and conflicts of 
interest by some of the experts.  As authors of the original paper, we find these three criticisms have 
over-generalised the evidence issue, failed to respect the knowledge and experience of the experts, 
and did not take into account the many measures to minimize potential bias. 
First, the lack of evidence. That criticism does not apply to smoked cigarettes and e-cigarettes.  
There is abundant evidence about the harm of cigarettes.  The paucity of evidence for serious harm 
to users of e-cigarettes over the years since they were first marketed in 2006, with millions 
purchased, is itself evidence. In addition, biomarkers of potential future harm are broadly 
reassuring3-5.   
Second, reliance on the opinions of the participants.  The approach we used in the study, decision 
conferencing6, sought from participants their expert judgements, not opinions.  The criteria and their 
definitions were taken from three drug harm studies, the ACMD’s original formulation7, the 2010 
study of UK drug harms published in the Lancet8, and the 2013 replication for EU drug harms9.   
Judgements about scores were based on data along with our knowledge and experience of the 
degree of harm, and plausible causal mechanisms for the harm.   When data were available, they 
were discussed openly by the group for their validity and reliability.  When data were sparse or 
lacking, we relied on logical inferences (e.g., the dearth of evidence of dying directly from an 
overdose of smoking led us to infer that cigarettes are not very harmful on that criterion, so we gave 
it a low score, but we assigned e-cigarettes a higher harm score for that effect because the nicotine 
solution in the cartridges could potentially be directly accessed).  A strength of the multi-criteria 
decision analysis (MCDA) model10 is that it incorporates both the data and judgements about the 
relevance of the data, thus capturing meaningful differences in the relative importance of the 
effects. 
Third, bias in the experts.  We selected participants who are recognised as experts by their 
publications, experience and generally-acknowledged professional standing, bringing diverse 
perspectives and expertise that could be relevant to assessing the harm from nicotine products. We 
included experts in behavioural pharmacology, legal aspects of tobacco control, smoking policy, 
toxicology, neuro-psychopharmacology, psychopharmacology, public health sciences and internal 
medicine, who collectively have published over 300 scientific publications relevant to understanding 
nicotine and tobacco harm.  It was misleading of the Lancet to characterise the authors as having 
“no prespecified expertise in tobacco control” as the project was about relative harms of nicotine 
products not tobacco policy. 
 
As for conflicts of interest, the decision conference process is designed to ensure that participants of 
different persuasions challenge each other, and the facilitator asks participants giving judgements to 
support them with studies, data or experience.  The facilitator ensured that peer review operated 
on-the-spot as the MCDA model was created in a step-by-step, structured process10.  Consistency 
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checks and sensitivity of overall results to the input scores and weights were thoroughly explored, 
with model results found to be very robust to imprecision in the data and the few disagreements 
among the experts. These procedures made it impossible for a single participant with a potential 
bias to have any meaningful influence on the process outcome. 
 
Potential sources of conflict of interest were disclosed at the meeting, and those in the prior three 
years were disclosed in the published paper.  We were informed by EuroSwiss Health that they have 
no funding from any tobacco or e-cigarette company; this was a requirement for accepting their 
funding.  Funds provided were not from tobacco or e-cigarette companies, and as stated in the 
paper, EuroSwiss Health and Lega Italiana Anti Fumo (LIAF) had no influence on the MCDA process. 
 
We are confident that the nicotine products study applied an appropriate structured process with a 
requisite diversity of experts who engaged in constructive discourse in building a model that 
represented the most scientifically sound assessment of the relative harms of nicotine products.  
Our model’s results for harms to the user provided Public Health England with the basis for their 
correct calculation of the estimate that e-cigarettes are 95% less harmful to the user than smoking.  
Or, as we prefer, smoking is estimated to be 20 times more harmful to the user than vaping. 
(745 words) 
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